Expanded Carrier Screening Market Report 2026

The expanded carrier screening market size has grown rapidly in recent years. It will grow from $2.46 billion in 2025 to $2.87 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to increasing awareness of inherited genetic disorders, expansion of prenatal screening programs, improvements in genetic sequencing accuracy, growing availability of diagnostic laboratories, rising clinician adoption of carrier screening tools.

The expanded carrier screening market size is expected to see rapid growth in the next few years. It will grow to $5.28 billion in 2030 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to increasing demand for personalized reproductive health solutions, rising integration of ai-based variant interpretation, expansion of population-wide screening initiatives, growing investments in genomic data platforms, increased focus on preventive genetic healthcare. Major trends in the forecast period include increasing adoption of pan-ethnic genetic screening panels, rising demand for preconception carrier testing, growing use of next-generation sequencing technologies, expansion of direct-to-provider genetic testing services, enhanced focus on genetic counseling integration.

The rising prevalence of genetic diseases is expected to drive the growth of the expanded carrier screening market in the coming years. Genetic diseases are disorders caused by abnormalities or mutations in an individual’s DNA, which can be inherited or occur spontaneously. Their increasing prevalence is largely due to advancements in diagnostic technologies, particularly next-generation sequencing and other genomic tools, which have greatly enhanced the detection and identification of genetic disorders that were previously undiagnosed or misclassified. Expanded carrier screening enables the identification of carriers before symptoms appear, supporting informed reproductive decisions and reducing the risk of passing inherited conditions to future generations. For example, in October 2024, the UK-based Cystic Fibrosis Trust reported that cystic fibrosis patient registrations rose from 11,148 in 2022 to 11,318 in 2023, reflecting a 1.5% year-over-year increase. Therefore, the growing prevalence of genetic diseases is fueling the carrier screening market.

Key players in the expanded carrier screening market are focusing on innovative solutions, such as comprehensive next-generation sequencing (NGS) panels, to detect a wide range of genetic conditions with high accuracy and efficiency. NGS-based panels analyze multiple genes simultaneously to identify numerous inherited disorders quickly and precisely. For instance, in February 2023, Fulgent Genetics Inc., a US-based genomic testing company, launched the Beacon787 Expanded Carrier Screening Panel, which evaluates 787 genes associated with severe inherited conditions. The panel provides extensive coverage of over 700 autosomal recessive and X-linked disorders, including all Tier 3 genes, leveraging advanced NGS technology for high analytical accuracy, a pan-ethnic approach, and a turnaround time of 2-3 weeks, making it one of the most comprehensive reproductive carrier screening solutions available.

In January 2024, Natera Inc., a US-based genetic testing company, acquired reproductive health assets from Invitae Corporation for $52.5 million. Through this acquisition, Natera aims to expand its reproductive health portfolio by integrating Invitae’s carrier screening and non-invasive prenatal testing services, while Invitae focuses on its core oncology and rare disease genetic testing operations. Invitae Corporation is a US-based genetic information company offering comprehensive genetic testing services, including carrier screening, diagnostic testing, and hereditary disease analysis.

Major companies operating in the expanded carrier screening market are Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific SE, Illumina Inc., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BGI Genomics Co. Ltd., Ambry Genetics Corporation, GeneDx Inc., BillionToOne Inc., MedGenome Labs Ltd., Centogene N.V., Baylor Miraca Genetics Laboratories LLC, Victorian Clinical Genetics Services, Pathkind Diagnostics Private Limited, Medicover Genetics GmbH, NxGen MDx LLC, GeneTech.

North America was the largest region in the expanded carrier screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the expanded carrier screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the expanded carrier screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the expanded carrier screening market by increasing costs of imported sequencing instruments, reagents, bioinformatics software, and laboratory automation equipment. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces cost pressures on testing kit manufacturing and exports. These tariffs are elevating testing costs and slowing technology upgrades. However, they are also encouraging domestic production of genetic testing consumables, regional sequencing infrastructure development, and innovation in cost-efficient screening platforms.

The expanded carrier screening market research report is one of a series of new reports that provides expanded carrier screening market statistics, including expanded carrier screening industry global market size, regional shares, competitors with a expanded carrier screening market share, detailed expanded carrier screening market segments, market trends and opportunities, and any further data you may need to thrive in the expanded carrier screening industry. This expanded carrier screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Expanded carrier screening is a type of genetic test that examines a wide panel of genes to determine whether individuals carry mutations linked to inherited genetic disorders. It is commonly performed before or during pregnancy to evaluate the risk of passing genetic conditions to offspring, regardless of ethnicity or family history.

The primary types of expanded carrier screening are customized panel testing and pre-designed panel testing. Customized panel testing involves genetic tests tailored to an individual’s specific family history, ethnicity, or medical needs to identify potential carrier risks. These tests use technologies such as DNA sequencing, polymerase chain reaction (PCR), microarrays, and others, and are applied in preconception and prenatal screening. Key end-users include hospitals, diagnostic laboratories, research laboratories, specialty clinics, and other healthcare providers.

The expanded carrier screening market consists of revenues earned by entities by providing services such as genetic panel testing, counseling services, bioinformatics analysis, sample collection and processing, and customized panel design. The market value includes the value of related goods sold by the service provider or included within the service offering. The expanded carrier screening market also includes sales of next-generation sequencing (NGS) panels, microarray-based screening kits, sample collection kits, lab automation systems, and genotyping assays. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.